J Korean Med Assoc.  2002 Feb;45(2):206-215. 10.5124/jkma.2002.45.2.206.

Growth Hormone Therapy

• Kim SW

• KMID: 2347644
• DOI: http://doi.org/10.5124/jkma.2002.45.2.206

Abstract

The safe clinical practice of growth hormone(GH) replacement requires judgement of the overall GH status, however, there is no biological marker for this in adults. In addition, diverse actions of GH in healthy individuals render the assessment of optimal GH replacement difficult. As in other fields of clinical practice, strategies and protocols vary between centers, however, most physicians experienced in pituitary diseases agree that GH replacement should begin at low doses, and increased to the final maintenance dose. The adequacy replacement is best determined by combination of clinical response and serum IGF-I, level avoiding supraphysiological levels of this GH-dependent peptide. Actually, GH can reduce body fat and restore muscles, bones, and quality of life. Appropriate using of GH will elicit antiaging effects.

Keyword

Growth hormone; Replacement therapy; Abdominal obesity syndrome; Osteoporosis; Quality of life

MeSH Terms

Adipose Tissue
Adult
Biomarkers
Growth Hormone*
Humans
Insulin-Like Growth Factor I
Muscles
Osteoporosis
Pituitary Diseases
Quality of Life
Biomarkers
Growth Hormone
Insulin-Like Growth Factor I